NCT07562087Phase 2Active not recruiting

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-10Estimated
Enrollment · participants722Actual
Source updated2026-07-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 700 participants (planned). After: 722 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source